Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Probenecid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 known ✓ | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 known ✓ | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLC22A11 known ✓ | Q9NSA0 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 14/20 | 1.00 |
| ▸ | CA12 | O43570 | 13/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 1.00 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 9/20 | 0.69 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probenecid SCHEMBL3663 | 1.00 | CA9 (1.00) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636804 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636803 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL28892826 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23630240 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL23391020 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL22325443 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636778 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL20636781 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 | |
| Probenecid SCHEMBL28422402 | 0.98 | CA9 (0.97) | CA9CA12CA2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199936-B1 | AUTOMATIC TISSUE DYEING APPARATUS AND AUTOMATIC TISSUE DYEING METHOD | NICHIREI BIOSCIENCES INC (JP) | 2023-12-20 | — | — | EP | claimed |
| EP-3575793-B1 | A METHOD OF DIAGNOSING CANCER BASED ON LIPIDOMIC ANALYSIS OF A BODY FLUID | FONS JK GROUP A S (CZ) | 2023-07-19 | — | — | EP | claimed |
| EP-2723233-B1 | MANAGEMENT METHOD AND SYSTEM FOR IMPLEMENTATION, EXECUTION, DATA COLLECTION, AND DATA ANALYSIS OF A STRUCTURED COLLECTION PROCEDURE WHICH RUNS ON A COLLECTION DEVICE | ROCHE DIABETES CARE GMBH (DE) | 2022-05-18 | — | — | EP | claimed |
| EP-3158336-B1 | IMPROVED IMMUNOASSAY METHODS | ONCIMMUNE LTD (GB) | 2018-08-22 | — | — | EP | claimed |
| EP-2831560-B1 | Composition, use of the composition and method for processing histological and cytological samples post mortem | MADAU GIACOMO (IT) | 2018-06-27 | — | — | EP | claimed |
| EP-2372367-B1 | A computer-implemented method for operating an automated sample workcell | HOFFMANN LA ROCHE (CH) | 2016-05-11 | — | — | EP | claimed |
| EP-2444812-B1 | IMPROVED IMMUNOASSAY METHODS | ONCIMMUNE LTD (GB) | 2015-12-02 | — | — | EP | claimed |
| EP-2107482-B1 | Method and system for analyzing reactions using an information system | ABBOTT LAB (US) | 2014-06-25 | — | — | EP | claimed |
| EP-2062053-B1 | IMPROVED IMMUNOASSAY METHODS | ONCIMMUNE LTD (GB) | 2012-12-05 | — | — | EP | claimed |
| EP-1821102-B1 | Method for discrimination of metaplasias from neoplastic or preneoplastic lesions | MTM LAB AG (DE) | 2011-01-26 | — | — | EP | claimed |
| EP-1913366-B1 | GRATING-BASED SENSOR COMBINING LABEL-FREE BINDING DETECTION AND FLUORESCENCE AMPLIFICATION | SRU BIOSYSTEMS INC (US) | 2010-06-09 | — | — | EP | claimed |
| EP-1889059-B1 | IMPROVED IMMUNOASSAY METHODS | ONCIMMUNE LTD (GB) | 2009-07-08 | — | — | EP | claimed |
| EP-1373553-B1 | METHOD FOR EXTRACTING INTACT MICRO-ORGANISMS FROM SLUDGE OR BIOFILMS | UNIV LIEGE (BE) | 2007-06-13 | — | — | EP | claimed |
| WO-2023232304-A1 | METHOD AND KIT FOR SIMULTANEOUSLY VERIFYING A PLURALITY OF DIFFERENT PATHOGENS IN A SAMPLE | Xebios Diagnostics Group GmbH (DE) | 2023-12-07 | — | — | WO | disclosed |
| EP-4286530-A1 | METHOD AND KIT FOR SIMULTANEOUSLY DETECTING A PLURALITY OF DIFFERENT PATHOGENS IN A SAMPLE | Xebios Diagnostics Group GmbH (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2013144191-A1 | SUBSTITUTED 2-AMINO-3-CYANOPYRIDINES AS INHIBITORS OF SODIUM-CALCIUM EXCHANGE AND USE THEREOF FOR CARDIOVASCULAR DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| EP-1206670-B1 | LYOPHILIZATION METHOD | BAYER HEALTHCARE AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1206670-A1 | LYOPHILIZATION METHOD | Bayer Aktiengesellschaft (DE) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001009559-A1 | LYOPHILIZATION METHOD | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-08 | — | — | WO | disclosed |
| WO-1997005663-A1 | CONVERTER FOR GENERATING ELECTRIC ENERGY (HOT-COLD CURRENT-GENERATING ELEMENT) | SEIBOLD HANS K (DE) | 1997-02-13 | — | — | WO | disclosed |